Rothman Richard B, Carroll F Ivy, Morales Marisela, Rowley Daniel L, Rice Kenner C, Dersch Christina M, Donovan David M
IRP, NIDA, NIH, Baltimore, Maryland 21224, USA.
Synapse. 2002 May;44(2):94-105. doi: 10.1002/syn.10060.
Previous work suggested that the cocaine analog [(125)I]RTI-55 labels a novel binding site in rat brain membranes, which is not associated with the dopamine (DA), serotonin (5-HT), or norepinephrine (NE) transporters [Rothman et al. 1995 J Pharmacol Exp Ther 274:385-395]. Here, we tested whether this site is a product of the DA transporter (DAT) gene. We used a T-antigen knock-in at the DAT gene that results in an effective DAT knock-out (KO) confirmed by Southern blot, DAT immunohistochemistry, and [(125)I]RTI-55 ligand binding. Brain membranes were prepared from frozen whole brain minus caudate of wild-type (WT) B6/Sv129, +/+ and minus sign/minus sign (KO) mice. KO mice were used at approximately 23 days of age. Binding surface analysis of [(125)I]RTI-55 binding to membranes prepared from the brains of WT mice, with 100 nM citalopram to block binding to the 5-HT transporter (SERT), revealed two binding sites: the DAT and a second site, replicating previous studies conducted with rat brains. In the absence of the DAT (minus sign/minus sign mice), binding surface analysis demonstrated that [(125)I]RTI-55 labeled two sites: the NET and a second site called site "X." Structure-activity studies of site "X" demonstrated that high-affinity ligands for the DAT, NET, and SERT have low or negligible affinity for site "X." The relatively high density of site "X" in brain membranes and the fact that the K(i) values of cocaine and cocaethylene for site "X" are in the range achieved in the brain following cocaine administration suggests that site "X" could contribute to the pharmacological or toxicological effects of cocaine. Further progress in delineating the function of site "X" will depend on developing potent and selective agents for this site.
先前的研究表明,可卡因类似物[(125)I]RTI-55可标记大鼠脑膜中的一种新型结合位点,该位点与多巴胺(DA)、5-羟色胺(5-HT)或去甲肾上腺素(NE)转运体无关[罗斯曼等人,1995年,《药理学与实验治疗学杂志》274:385-395]。在此,我们测试了该位点是否为DA转运体(DAT)基因的产物。我们在DAT基因处进行了T抗原敲入,通过Southern印迹、DAT免疫组织化学和[(125)I]RTI-55配体结合证实产生了有效的DAT基因敲除(KO)。从野生型(WT)B6/Sv129、+/+和-/- (KO)小鼠的冷冻全脑(不含尾状核)制备脑膜。KO小鼠在约23日龄时使用。用100 nM西酞普兰阻断与5-HT转运体(SERT)的结合,对[(125)I]RTI-55与WT小鼠脑制备的膜的结合表面分析显示有两个结合位点:DAT和第二个位点,重复了先前对大鼠脑进行的研究。在没有DAT的情况下(-/-小鼠),结合表面分析表明[(125)I]RTI-55标记了两个位点:去甲肾上腺素转运体(NET)和第二个称为位点“X”的位点。位点“X”的构效关系研究表明,对DAT、NET和SERT具有高亲和力的配体对位点“X”的亲和力很低或可忽略不计。脑膜中位点“X”的相对高密度以及可卡因和可卡因乙烯对位点“X”的抑制常数(Ki)值处于可卡因给药后在脑中达到的范围内,这表明位点“X”可能促成了可卡因的药理或毒理作用。阐明位点“X”功能的进一步进展将取决于开发针对该位点的强效和选择性药物。